Why Humanigen Stock Is Down Today
Shares of Humanigen (NASDAQ: HGEN) were down by 8.6% as of 12:50 p.m. EST Wednesday, after having fallen by as much as 13% earlier in the trading day. The catalyst for these losses seems to be an update the clinical-stage biopharmaceutical company delivered regarding its phase 3 clinical trial for lenzilumab in patients hospitalized with COVID-19.
The phase 3 study in question originally started in late April 2020, and its primary endpoint was time to recovery for coronavirus patients. In a regulatory filing submitted Tuesday night, Humanigen said it was changing the primary endpoint to ventilator-free survival through day 28. Time to recovery will now be one of the study's secondary endpoints.
Image source: Getty Images.
Source Fool.com
